Deutsche Bank Reiterates “$367.00” Price Target for Regeneron Pharmaceuticals (REGN)
Deutsche Bank set a $367.00 target price on Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report released on Tuesday morning. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.
REGN has been the subject of several other reports. Canaccord Genuity reissued a buy rating and issued a $522.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, February 7th. JPMorgan Chase & Co. upped their target price on Regeneron Pharmaceuticals from $455.00 to $457.00 and gave the stock a neutral rating in a research report on Wednesday, January 24th. Zacks Investment Research lowered Regeneron Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, February 5th. Evercore ISI dropped their target price on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an outperform rating on the stock in a research report on Thursday, November 16th. Finally, Guggenheim set a $530.00 target price on Regeneron Pharmaceuticals and gave the stock a buy rating in a research report on Friday, February 9th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $449.49.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) opened at $337.75 on Tuesday. The stock has a market capitalization of $37,106.66, a PE ratio of 24.93, a P/E/G ratio of 1.08 and a beta of 1.54. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18. Regeneron Pharmaceuticals has a one year low of $313.53 and a one year high of $543.55.
In other news, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 10.80% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of REGN. Ark Investment Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 78.8% during the 2nd quarter. Ark Investment Management LLC now owns 1,234 shares of the biopharmaceutical company’s stock valued at $606,000 after acquiring an additional 544 shares during the last quarter. Andra AP fonden increased its holdings in shares of Regeneron Pharmaceuticals by 120.0% during the 3rd quarter. Andra AP fonden now owns 2,200 shares of the biopharmaceutical company’s stock valued at $984,000 after acquiring an additional 1,200 shares during the last quarter. Chicago Equity Partners LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $675,000. Bessemer Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 952.4% during the 3rd quarter. Bessemer Group Inc. now owns 663 shares of the biopharmaceutical company’s stock valued at $297,000 after acquiring an additional 600 shares during the last quarter. Finally, Global X MANAGEMENT CO LLC increased its holdings in shares of Regeneron Pharmaceuticals by 10.7% during the 3rd quarter. Global X MANAGEMENT CO LLC now owns 1,334 shares of the biopharmaceutical company’s stock valued at $596,000 after acquiring an additional 129 shares during the last quarter. 66.40% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/03/14/deutsche-bank-reiterates-367-00-price-target-for-regeneron-pharmaceuticals-regn.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.